Seoul, South Korea – DaeWon Pharmaceutical has announced the launch of Pelubi-S, an enhanced version of its popular analgesic, Pelubi. The new drug is set to further solidify the company's position in the nonsteroidal anti-inflammatory drug (NSAID) market.

Pelubi, a domestically developed drug approved in 2007, has been a mainstay in South Korea for treating pain and inflammation. Its versatility expanded in 2017 when it was approved for treating fever associated with acute upper respiratory tract infections. The COVID-19 pandemic further boosted its demand as it became a go-to treatment for respiratory symptoms.

The newly introduced Pelubi-S addresses some of the limitations of its predecessor. By incorporating tromethamine, the drug's solubility has been significantly improved, ensuring faster and more efficient absorption. This enhancement is particularly notable in acidic environments, where the original Pelubi exhibited lower solubility.

Additionally, Pelubi-S has shown a marked reduction in gastrointestinal side effects, a common complaint with NSAIDs. Comparative studies have revealed a substantial decrease in the severity of stomach lining damage in patients treated with Pelubi-S.

"Pelubi-S offers patients a faster-acting and gentler option for pain relief," said a representative from DaeWon Pharmaceutical. "With its improved solubility and reduced gastrointestinal side effects, Pelubi-S represents a significant advancement in the treatment of pain and inflammation."

The company has reported that the Pelubi series, including Pelubi and Pelubi CR, achieved sales of 62.2 billion won in 2022, making it the top-selling NSAID in South Korea. DaeWon Pharmaceutical is optimistic that Pelubi-S will further strengthen its market dominance.